DGXNEUTRAL

Revenue Growth (YoY)

9.2%

Higher than 59% of Healthcare sector peers

Updated 320h ago

Sector Performance

59th percentile

DGX

9.2%

Sector Median

6.2%

Sector Avg

4.2%

📊

Deep Analysis

Quest Diagnostics' revenue growth of 9.2% year-over-year means its sales from the most recent quarter were 9.2% higher than the same quarter last year, indicating expansion.

Among Healthcare sector peers, this exceeds the median of 6.2% and places the company in the 59th percentile. However, the year-over-year change in the metric itself is not available (N/A), the quarter-over-quarter change is N/A, and there is no trend direction for the last eight quarters — only a single historical value of 9.2% is provided. With no trend data, it is impossible to assess whether the growth rate is accelerating, decelerating, or stable. The above-median level alone suggests a moderate opportunity relative to peers, but the absence of trend information makes the risk profile unclear. This metric neither supports nor contradicts the overall NEUTRAL verdict, as a single point above the median does not provide enough context to shift the rating either way.

Frequently Asked Questions

What does the Revenue Growth (YoY) tell investors about DGX?

Year-over-year revenue acceleration is one of the strongest signals of business momentum. Sustained >15% growth is rare and typically re-rated by the market.

How is the Revenue Growth (YoY) calculated?

Revenue Growth (YoY) is calculated as: (Revenue_t - Revenue_t-4) / Revenue_t-4.

How does DGX's Revenue Growth (YoY) compare to its sector?

DGX's Revenue Growth (YoY) of 9.2% compares to a Healthcare sector median of 6.2%, placing it in the 59th percentile.

Who are DGX's closest peers by Revenue Growth (YoY)?

The closest Healthcare peers by Revenue Growth (YoY) include: ALGN (6.2%), AMGN (5.8%), CPRX (5.6%), ABT (7.8%), ZBH (9.3%).

The Formula

(Revenue_t - Revenue_t-4) / Revenue_t-4

Why It Matters

Year-over-year revenue acceleration is one of the strongest signals of business momentum. Sustained >15% growth is rare and typically re-rated by the market.